Table 3. Baseline characteristics, G8 score and Comprehensive Geriatric Assessment (CGA) associated with overall survival among *clinically fit* older patients with malignant haemopathies : univariate analysis (n=90)

	One-year OS (%)	P
Age		0.010
65-74 years	84%	
≥75 years	59%	
Gender		0.040
Men	65%	
Women	82%	
Diagnosis		
Favorable prognosis*	80%	<0.001
Unfavorable prognosis**	33%	
Very unfavorable prognosis***	/	
Performance status		0.495
Normal (≤1/5)	71%	
Abnormal (>1/5)	76%	
Initial treatment choice**		0.052
Full dose chemotherapy	79%	
Reduced-dose chemotherapy	59%	
Tolerance to treatment		0.979
No intolerence to treatment	72%	
Intolerance to treatment	73%	
G8 score		0.988
Not vulnerable	72%	
Vulnerable	72%	
CGA total score		0.999
Not vulnerable	72%	
Vulnerable	72%	
Functional status		0.122
No limitation	78%	
Any limitation	64%	
Risk of falls status		0.500
Not vulnerable	73%	
Vulnerable	64%	
Fatigue status		0.578
Not vulnerable	72%	
Vulnerable	77%	
Nutritional status		0.946
Not vulnerable	76%	
Vulnerable	74%	
Cognitive status		0.013
No cognitive impairment	88%	
Cognitive impairment	63%	
Emotional status		0.884
Not vulnerable	73%	
Vulnerable	70%	
Polypharmacy		0.268
Not vulnerable	67%	
Vulnerable	78%	
Comorbidities		0.399
Not vulnerable	77%	
Vulnerable	69%	

*Chronic Lymphocytic Leukaemia, Lymphoma, Multiple Myeloma

**Acute Myelogenous Leukaemia, Chronic Myelomonocytic Leukaemia, Myelodysplasia, Myeloproliferative Neoplasms

***Acute Lymphocytic Leukaemia

****An initial full-dose or reduced-dose chemotherapy has been administrated to patients according to a multidisciplinary team decision